Ona Therapeutics strengthens leadership team

Barcelona, Spain-based biotech Ona Therapeutics today announced key leadership appointments to support its rapid growth and pipeline advancement.

Dr Aleix Prat, a global leader in drug and biomarker development, has been appointed chairman of the advisory Board. Additionally, Dr Jutta Amersdorffer has joined as chief medical officer and Stéphane Durant des Aulnois as chief financial officer.

These appointments come at a pivotal time as Ona accelerates the development of its first-in-class antibody-drug conjugates (ADC) therapeutics, targeting novel tumor-specific markers to eliminate hard-to-treat, resistant cancer cells and advance its pipeline toward clinical development across multiple cancer types, the company noted.